A high-quality medical device franchise with a wide economic moat, four consecutive quarterly beats, and 51.7% headroom to the analyst-based target is currently in a confirmed technical downtrend following a death cross — the quality and fundamental case is intact but entry requires patience until momentum conditions stabilize. The risk/reward of 8.31-to-1 is asymmetrically favorable for holders willing to absorb near-term technical pressure.
Thesis pillars
- High Quality Wide Moat Franchise→Stable
- Four Quarter Beat Streak↑Improving
- Momentum Confirmed Downtrend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Boston Scientific Corporation (BSX) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $44.29, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source components; Earnings in 4 days (event risk).
Boston Scientific develops, manufactures, and markets medical devices across two reportable segments — MedSurg and Cardiovascular — for use in interventional cardiology, electrophysiology, urology, endoscopy, neuromodulation, and oncology procedures sold in 127 countries.... Read more
Hold if already holding. Not a fresh buy at $44.29, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source components; Earnings in 4 days (event risk). Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Score 6.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: speculative.
About Boston Scientific Corporation
About Boston Scientific Corporation
Boston Scientific's two reportable segments — MedSurg and Cardiovascular — serve hospitals and clinics in 127 countries, with international net sales at 36% of global net sales in 2025. The FARAPULSE Pulsed Field Ablation System, launched in 2024, became the predominant component of Electrophysiology business-unit revenue following FDA expanded labeling approval for persistent atrial fibrillation in the second quarter of 2025. On January 15, 2026, the company announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, to be funded largely through approximately $11 billion in new debt.
Boston Scientific markets a broad range of single-use and implantable devices across endoscopy, urology, neuromodulation, ICVT, WATCHMAN left atrial appendage closure, electrophysiology, CRM, and interventional oncology. Sales flow primarily through dedicated direct sales forces, supplemented by distributors in markets where direct presence is not cost-effective, reaching hospitals, clinics, outpatient facilities, and medical offices in 127 countries. In China, the company faces competition from domestic device manufacturers that may benefit from local-supplier preferences in tender processes. Certain materials and components are purchased from single sources due to quality considerations, expertise, or regulatory constraints, and the 10-K acknowledges ongoing risk from certain vendors that could result in increased costs or supply interruption. The pending Penumbra acquisition would raise total debt well above the $11.436 billion outstanding as of December 31, 2025, increasing financial leverage during the integration period.
Show full overview
Single-source component supply poses a structural manufacturing risk: certain items are custom-made or sourced from a single supplier due to quality, expertise, cost, or regulatory constraints — a situation the 10-K describes as carrying ongoing vendor risk. Boston Scientific's global manufacturing footprint and tariff exposure compound this: the company cites U.S. trade tariff and policy uncertainty as a factor that may affect its ability to source and manufacture products cost-effectively, and faces potential retaliatory measures that could limit access to international markets. No specific mitigation timeline is disclosed beyond the existing supplier resiliency program.
See also: Healthcare · Medical Devices
From Boston Scientific Corporation's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-26Recent Developments — Boston Scientific Corporation
Latest news
- NEWS Boston Scientific Corporation (BSX): Stephen Mandel Opens New Position in Medical Device Firm - Yahoo Finance — Yahoo Finance positive
- NEWS Boston Scientific (BSX) stock sinks as market gains: Here's why - MSN — MSN negative
- NEWS SHAREHOLDER ALERT Securities Class Action Filed Against Boston Scientific Corporation (BSX) - TMX Newsfile — TMX Newsfile negative
- NEWS Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance - The Mo — The Motley Fool negative
- NEWS Boston Scientific Is the Worst Performing S&P 500 Stock. Here’s Why. - Barron's — Barron's negative
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicinternational net sales36%10-K Item 1A: 'International net sales accounted for 36 percent of our global net sales in 2025'
- HIGHSuppliersingle-source components10-K Item 1: 'certain materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements'
- MEDIUMProductFARAPULSE10-K Item 1: 'FARAPULSE™ PFA System ... the predominant component of our Electrophysiology business unit and revenue'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $44.29, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source components; Earnings in 4 days (event risk). Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Target $65.19 (+47.2%), stop $41.49 (−6.7%), A.R:R 7.6:1. Score 6.9/10, moderate confidence.
Take-profit target: $65.19 (+47.3% upside). Target $65.19 (+47.2%), stop $41.49 (−6.7%), A.R:R 7.6:1. Stop-loss: $41.49.
Concentration risk — Supplier: single-source components; Earnings in 4 days (event risk); Below 200-MA, MA slope -10.3%/30d (confirmed downtrend).
Boston Scientific Corporation trades at a P/E of 18.5 (forward 11.9). TrendMatrix value score: 8.1/10. Verdict: Hold.
39 analysts cover BSX with a consensus score of 4.1/5. Average price target: $72.
What does Boston Scientific Corporation do?Boston Scientific develops, manufactures, and markets medical devices across two reportable segments — MedSurg and...
Boston Scientific develops, manufactures, and markets medical devices across two reportable segments — MedSurg and Cardiovascular — for use in interventional cardiology, electrophysiology, urology, endoscopy, neuromodulation, and oncology procedures sold in 127 countries. International net sales represented 36% of global net sales in 2025; outstanding debt was $11.436 billion as of December 31, 2025, with a pending ~$14.5 billion acquisition of Penumbra announced January 15, 2026.